Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cyclerion Therapeutics (CYCN) Consolidated Net Income (2018 - 2025)

Cyclerion Therapeutics has reported Consolidated Net Income over the past 6 years, most recently at -$1.0 million for Q3 2025.

  • For Q3 2025, Consolidated Net Income changed N/A year-over-year to -$1.0 million; the TTM value through Dec 2025 reached -$4.1 million, changed N/A, while the annual FY2023 figure was $7.3 million, 128.38% up from the prior year.
  • Consolidated Net Income for Q3 2025 was -$1.0 million at Cyclerion Therapeutics, up from -$1.7 million in the prior quarter.
  • Over five years, Consolidated Net Income peaked at $13.5 million in Q3 2023 and troughed at -$16.2 million in Q2 2021.
  • A 4-year average of -$6.2 million and a median of -$4.9 million in 2022 define the central range for Consolidated Net Income.
  • Biggest five-year swings in Consolidated Net Income: increased 3.07% in 2022 and later skyrocketed 321.28% in 2023.
  • Year by year, Consolidated Net Income stood at -$14.3 million in 2021, then surged by 79.82% to -$2.9 million in 2022, then skyrocketed by 565.74% to $13.5 million in 2023, then crashed by 107.47% to -$1.0 million in 2025.
  • Business Quant data shows Consolidated Net Income for CYCN at -$1.0 million in Q3 2025, -$1.7 million in Q2 2025, and -$1.5 million in Q1 2025.